Edition:
United States

Biotechnology & Medical Research

Page 2

Mesoblast Ltd says Co and Mallinckrodt enter into agreement

Thursday, 22 Dec 2016 04:54pm EST

Mesoblast Ltd : Asx alert-Mesoblast and Mallinckrodt enter into agreement-MSB.AX . Mallinckrodt will have exclusive period of up to 9 months to conclude commercial,development agreements for 2 product candidates in all territories outside of Japan and China .Mallinckrodt will purchase approximately 20.04 million of Mesoblast's ordinary shares at a price of A$1.4761 per share.

Dipexium and PLX Pharma announce merger agreement

Thursday, 22 Dec 2016 04:39pm EST

Dipexium Pharmaceuticals Inc : Dipexium Pharmaceuticals -following closing, dipexium will be renamed PLX Pharma Inc, and will operate under leadership of PLX management team . Dipexium Pharmaceuticals Inc - co to issue about 36 million new shares of common stock to PLX stockholders under exchange ratio formula . Dipexium Pharmaceuticals Inc - boards of directors of both Dipexium and PLX Pharma have unanimously approved proposed transaction . Dipexium Pharmaceuticals Inc - PLX stockholders will receive newly issued shares of common stock of Dipexium . Dipexium and PLX Pharma announce merger agreement . Dipexium Pharmaceuticals Inc - upon closing of merger, existing PLX stockholders are expected to own 76.75% of Dipexium common shares outstanding . Dipexium Pharmaceuticals Inc - Michael Valentino to serve as executive chairman of board and Natasha Giordano to serve as president and CEO of combined co . Dipexium Pharmaceuticals Inc - upon closing of merger, existing Dipexium stockholders are expected to own 23.25% of Dipexium common shares outstanding . Dipexium Pharmaceuticals Inc -upon closing the merger, existing PLX stockholders are expected to own 76.75% of Dipexium common shares outstanding .Dipexium and PLX Pharma announce merger agreement.

Peptron to buy land and building for 4.43 bln won

Thursday, 22 Dec 2016 04:56am EST

Peptron Inc <087010.KQ> : Says it will buy land and building located in Osong 2-jigu, Korea .Says transaction amount is 4.43 billion won and transaction settlement date is Dec. 20, 2019.

Benitec biopharma signs new research and collaboration agreement

Wednesday, 21 Dec 2016 05:42pm EST

Benitec Biopharma Ltd :New research and collaboration agreement has been signed with royal holloway university of london.

Sanofi in advanced talks to buy Actelion- Bloomberg, citing sources

Thursday, 15 Dec 2016 08:43pm EST

:Sanofi said to be in advanced talks to buy drugmaker Actelion, companies discussing price of about $275 per actelion share- bloomberg, citing sources.

Evotec confirms its liquidity guidance after Cyprotex acquisition

Thursday, 15 Dec 2016 01:30am EST

Evotec AG : Says completes acquisition of Cyprotex Plc . Confirms its liquidity guidance for 2016 .It is expected that Cyprotex business will add around 18-20 mln euros in revenues in 2017 and will be accretive to evotec's 2017 EBITDA.

Lonza to acquire Capsugel for $5.5 bln

Thursday, 15 Dec 2016 12:30am EST

Lonza Group Ag : Lonza to acquire Capsugel to create leading integrated solutions provider to the global pharma and consumer healthcare industries . Says to acquire Capsugel for $5.5 billion . Says transaction is expected to be core EPS accretive in first full year post closing . Says expects to achieve CHF 30 million p.a. operating synergies and CHF 15 million tax synergies per annum by year three . Says intends to retain current dividend policy and maintain about 3x net debt/EBITDA leverage . Says deal includes refinancing of existing Capsugel debt of approximately $2 billion . Says has committed debt financing for full acquisition amount from BofA Merrill lynch and UBS and plans to raise equity . Says financial package foresees refinancing of Lonza's current CHF 700 million revolving credit facility .Says all-cash acquisition of Capsugel will be financed with a combination of debt and equity financing.

Actelion says in discussions with another party regarding possible strategic transaction

Tuesday, 13 Dec 2016 08:11pm EST

Actelion Ltd : Actelion - Actelion is engaged in discussions with another party regarding a possible strategic transaction . Actelion update on strategic transaction discussions . Actelion - Confirms that J&J has withdrawn from the discussions .Actelion - There can be no certainty at this point that any transaction will result.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary